(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 12.44% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.53%.
Alpha Teknova's revenue in 2026 is $43,700,000.On average, 10 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,509,227,553, with the lowest TKNO revenue forecast at $2,304,514,271, and the highest TKNO revenue forecast at $2,615,691,345. On average, 10 Wall Street analysts forecast TKNO's revenue for 2027 to be $2,880,803,904, with the lowest TKNO revenue forecast at $2,681,352,070, and the highest TKNO revenue forecast at $3,061,035,346.
In 2028, TKNO is forecast to generate $3,368,024,736 in revenue, with the lowest revenue forecast at $3,157,352,059 and the highest revenue forecast at $3,523,291,144.